The stock of Alaunos Therapeutics Inc. (NASDAQ:TCRT) decreased by -$0.25 on Tuesday to finish at $0.14, down -64.68 percent. The last five days have seen an average of 4,831,820 shares of common stock traded. 5 times new highs were reached in the current year, with a fall of -$0.5101. The average number of shares traded over the last 20 days was 1,532,725, while the average volume over the last 50 days totaled 918,294.
TCRT stock dropped -71.28% since last month. On 08/15/23, the company’s shares reached a one-month low of $0.1215. The stock touched a high of $4.01 on 01/17/23, after rallying from a low of $0.38 in 52 weeks. The price of TCRT stock has declined by -78.59% or -$0.5101 this year, reaching a new high 5 times. Still, the stock price is down -96.53% from the 52-week high.
Insider Transactions
TCRT stock investors should be aware that Alaunos Therapeutics Inc. (TCRT) stock had its last reported insider trading activity 260 days ago on Nov 29. On Nov 29, Director Vieser Jaime acquired 1,250,000 shares at $0.65 each. This transaction resulted in the insider spending $812,500. On Nov 29, Postma Robert W added 750,000 shares at a price of US$0.65. After the transaction, the insider now owns 5,000,000 shares.
Valuation Metrics
Beta for the stock is 0.17. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 11.79, the price-to-book (PB) ratio of 1.16.
Financial Health
For the three months ended June 29, Alaunos Therapeutics Inc.’s quick ratio was 2.20, while its current ratio was 2.20, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $38.03 million and revenue of $2.92 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TCRT’s return on assets (ROA) during the last 12 months has been -59.60%. There was a -63.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -108.30%.
Earnings Surprise
According to Alaunos Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Alaunos Therapeutics Inc.’s quarterly earnings would be -$0.04, but it ended up being -$0.04. EBITDA was -$6.42 million for the quarter. At the end of Alaunos Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 6.28 million, while its total debt was $13.6 million. Equity owned by shareholders amounts to $240.63 million.
Technical Picture
Here’s a quick look at Alaunos Therapeutics Inc.’s (TCRT) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 9.04%, suggesting the stock is oversold, with a 502.28% historical volatility rate.
The stochastic %K and %D were 7.19% and 7.22% respectively, while the average true range (ATR) was 0.0569. Based on the 14-day stochastic reading of 4.81%, the RSI (14) reading is 14.69%. On the 9-day MACD Oscillator, the stock is at -0.0685, and the 14-day reading is at -0.0929.
Analyst Ratings
Analysts have assigned Alaunos Therapeutics Inc. (TCRT) an Overweight rating. TCRT is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is TCRT’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.50 and $7.50, with a median target price of $4.50. In analyzing these forecasts, the average price target given by analysts for Alaunos Therapeutics Inc. (TCRT) is $4.50.
